Clinical Trials Results - National Cancer Institute

Skip to content

NCI Home

Cancer Topics

Clinical Trials

Cancer Statistics

Research & Funding

News

About NCI


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 224 Show results per page	View Search Criteria \| Help With Results

	Title				Phase				Protocol IDs

	Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis				Phase IV				CZOL446EDE15 NCT00172003
	Sorafenib Hypophosphatemia Study				Phase IV				12345 N.A., NCT00622479
	Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma				Phase IV				A6181132 NCT00706706
	Comparison Between Surgery and Radiofrequency for Treatment of Renal Tumors				Phase III, Phase II				9359-03 2003-006, NCT00221728
	ABR-217620 With Interferon-Alpha (IFN-Alpha) Compared to IFN-Alpha Alone in Patients With Advanced Renal Cell Carcinoma				Phase III, Phase II				06762004 NCT00420888
	SU011248 versus Interferon-alfa as First-Line Systemic Therapy for Patients with Metastatic Renal Cell Carcinoma				Phase III				A6181034 NCT00083889
	Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma				Phase III				A6181037 NCT00130897
	Sunitinib or Sorafenib in Treating Patients With Kidney Cancer That Was Removed By Surgery				Phase III				ECOG-E2805 E2805, CALGB-E2805, SWOG-E2805, CAN-NCIC-E2805, NCT00326898
	Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking				Phase III				FCCC-FCRB-04-003-P FCRB-04-003-P, NCT00365508
	A Clinical Trial Comparing Efficacy and Safety of Sunitinib Versus Placebo for theTreatment of Patients at High Risk Of Recurrent Renal Cell Cancer				Phase III				A6181109 A6181109, NCT00375674


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute